A VUS in your genetic test result? Here is what it means and how we can reanalyze it.
A Variant of Uncertain Significance is not a diagnosis. It means that the available evidence is not yet sufficient to determine whether the variant causes a specific disease.
Our team independently reanalyzes the genetic test result using multiple scientific approaches to provide additional information that may support its interpretation in the clinical context.
We communicate our findings in both plain language for patients and families and detailed scientific language for healthcare professionals.
$129USD· Genetic test review, online, no appointment
- Independent of the laboratory that issued your report
- Scientific review, not medical care
- Rare disease expertise, more than 25 years
How laboratories classify a variant
- Benign
- Likely benign
- Uncertain significance (VUS)Your result
- Likely pathogenic
- Pathogenic
Uncertain means the evidence is incomplete, not that something is wrong with you.
A Variant of Uncertain Significance is a change in a gene that the laboratory found but could not classify as benign or as disease causing. The evidence available today is not sufficient to place it on either side.
That classification is not permanent. As more people are sequenced and more studies are published, variants move out of the uncertain category. Most move toward benign. A smaller number move toward pathogenic and finally explain a clinical picture that had no answer.
A VUS is not a diagnosis. It is a statement about the limits of today's evidence, and evidence changes.
Read the full patient guide to VUS resultsAn independent reading of your variant, against current standards.
We start from the report you already have and examine the finding ourselves, with no link to the laboratory that issued it.
Independent scientific review
Your variant is re-examined case by case, from several scientific perspectives, by a molecular genetics team that works with rare diseases.
Classification checked against ACMG criteria
We review how the variant stands against the ACMG and AMP criteria and against public evidence such as ClinVar and population frequency databases, and we explain each point in language you can follow.
Reanalysis when the evidence has moved
Literature, gene to disease associations and functional data published since your report can change the picture. We check whether they do, and we say so plainly when they do not.
Three steps, starting with the $129 review.
There is no free stage. The initial review is a paid first step, and it is what tells us whether a full in-depth reanalysis is worth doing in your case.
- 01
Start your $129 review
You create your account on our patient platform and pay the $129 initial review. That payment opens your case.
- 02
Send your report and clinical context
You upload the genetic test report, a short clinical summary and any relevant family history through a secure portal. No appointment and no travel.
- 03
Receive your plain-language report
Our team assesses the finding and writes back what the current evidence supports, and whether a full in-depth reanalysis is warranted in your case.
$129 USD, paid once to open your case. The full in-depth review is a separate stage with its own fee, and you only take it if you decide to.
A written report you can actually read.
Written for you, and detailed enough to hand to the physician who follows your case.
- Your variant explained in plain language: the gene, the change, and what the notation on your report means.
- Its current classification and the evidence behind it, set out criterion by criterion.
- What has been published since your original report, and whether it moves the classification.
- What can realistically be reanalysed, and what today's evidence still cannot resolve.
We do not issue diagnoses, prescribe treatment, or promise that a variant will be reclassified. The report describes what the science currently supports.
Professor Paul Laissue, MD, MSc, PhD
Scientific Director, PLH Genetics
Prof. Paul Laissue and the PLH Genetics scientific team.
Every case is reviewed and validated by Professor Paul Laissue, Scientific Director of PLH Genetics, with more than 25 years of research in molecular genetics, functional genomics and quantitative genetics.
The team works with rare disease findings and applies the international classification standards used by clinical laboratories worldwide, which is what makes a second, independent reading of the same variant meaningful.
- More than 25 years in molecular genetics
- Rare disease focus
- ACMG and AMP classification standards
What people ask us about a VUS
A VUS is not a diagnosis and it is not a positive result. It means the evidence available today is not enough to classify the variant in either direction. International guidelines advise against making clinical decisions on a VUS alone. What it does deserve is a careful reading in the context of your clinical picture.
It can happen. Classifications change as evidence accumulates, and reanalysis programmes regularly move variants out of the uncertain category, most often toward benign. We cannot promise that yours will change. What we can do is check whether the current evidence supports a different reading, and explain what we find either way.
No. This is an independent scientific review, not medical care. We do not diagnose, prescribe or manage treatment, and we do not establish a physician patient relationship. The report is written so that you can read it yourself and take it to the physician or genetic counsellor who follows your case.
The $129 initial review covers opening your case: you create your account, send your report and clinical context, and our team makes a first assessment to determine whether a comprehensive scientific reanalysis can be performed. The in-depth reanalysis is a separate stage with its own fee, and we tell you what it involves before you decide.
Yes. You register, upload your documents and receive the report through the platform. There are no in-person appointments and no travel.
Your report and personal data are stored encrypted, in transit and at rest, and access is restricted to the scientific team handling your case. We do not sell or share your information with third parties for marketing, and we share it with your physician only at your explicit request.
Your result deserves a second, independent reading.
If a VUS has left you without an answer, we can tell you what the current evidence supports and what it does not. Start with the $129 review.
$129USD· Genetic test review
This service provides an independent scientific review of reported genetic findings, for scientific and educational purposes. It does not constitute medical diagnosis, treatment, genetic counselling or medical advice, and it does not establish a physician patient relationship. All clinical decisions remain the responsibility of the treating healthcare professionals. PLH Genetics is a product of SIGNOS LLC.
$129 USD · Genetic test review · Online
Start your $129 review